Literature DB >> 16504994

Differential expression patterns of recombination-activating genes in individual mature B cells in juvenile idiopathic arthritis.

C Faber1, H Morbach, S K Singh, H J Girschick.   

Abstract

BACKGROUND: Re-expression of the recombination-activating genes (RAG) in peripheral B cells may be relevant in the development of autoreactive antibodies in autoimmune diseases. The presence of antinuclear antibodies (ANA) as a hallmark of oligoarticular juvenile idiopathic arthritis (o-JIA, early-onset type) indicates a breakdown in immunological tolerance. AIM: To examine the expression of RAG genes in peripheral blood mature B lymphocytes in patients with o-JIA.
METHODS: 777 memory B cells from peripheral blood, CD19+ CD27+ CD5+ or CD19+ CD27+ CD5-, isolated from three ANA+ children with o-JIA and three healthy age-matched children, were examined for the expression of RAG1 and RAG2 mRNA. mRNA transcripts of activation-induced cytidine deaminase and immunoglobulin G were searched to further determine their developmental stage.
RESULTS: mRNA was present for any of the two RAG genes in the B cells of children with JIA and controls. However, the predominance of RAG1 or RAG2 was different. A significantly decreased frequency of RAG2-expressing memory B cells in both CD5+ and CD5- populations was noted in children with JIA (p<0.001), whereas the number of RAG1-expressing B cells was slightly increased. The coordinate expression of both the RAG genes was a rare event, similar in the CD5+ populations (1% in controls, 2% in children with JIA), but different among the CD5- compartments (5% v 0%; p<0.01).
CONCLUSION: These results argue for a reduced coordinate RAG expression in the peripheral CD5- memory B cells of patients with o-JIA. Thus, it was hypothesised that impaired receptor revision contributes to autoimmune pathogenesis in JIA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504994      PMCID: PMC1798333          DOI: 10.1136/ard.2005.047878

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  39 in total

1.  International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

Authors:  Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

Review 2.  V(D)J recombination: molecular biology and regulation.

Authors:  D G Schatz; M A Oettinger; M S Schlissel
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

Review 3.  V(D)J recombination and the cell cycle.

Authors:  W C Lin; S Desiderio
Journal:  Immunol Today       Date:  1995-06

4.  Cell cycle regulation of V(D)J recombination-activating protein RAG-2.

Authors:  W C Lin; S Desiderio
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

5.  RAG mutations in human B cell-negative SCID.

Authors:  K Schwarz; G H Gauss; L Ludwig; U Pannicke; Z Li; D Lindner; W Friedrich; R A Seger; T E Hansen-Hagge; S Desiderio; M R Lieber; C R Bartram
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

6.  RAG-1-deficient mice have no mature B and T lymphocytes.

Authors:  P Mombaerts; J Iacomini; R S Johnson; K Herrup; S Tonegawa; V E Papaioannou
Journal:  Cell       Date:  1992-03-06       Impact factor: 41.582

7.  RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement.

Authors:  Y Shinkai; G Rathbun; K P Lam; E M Oltz; V Stewart; M Mendelsohn; J Charron; M Datta; F Young; A M Stall
Journal:  Cell       Date:  1992-03-06       Impact factor: 41.582

8.  Recombination activating genes (RAG) induce secondary Ig gene rearrangement in and subsequent apoptosis of human peripheral blood circulating B lymphocytes.

Authors:  H Nagafuchi; H Yoshikawa; Y Takeba; K Nara; K Miura; M S Kurokawa; N Suzuki
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

9.  Receptor editing in self-reactive bone marrow B cells.

Authors:  S L Tiegs; D M Russell; D Nemazee
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

10.  Human lupus anti-DNA autoantibodies undergo essentially primary V kappa gene rearrangements.

Authors:  C Bensimon; P Chastagner; M Zouali
Journal:  EMBO J       Date:  1994-07-01       Impact factor: 11.598

View more
  7 in total

1.  Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus.

Authors:  Lynda Mazari; Meryem Ouarzane; Moncef Zouali
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-02       Impact factor: 11.205

2.  Phosphorothioate-modified CpG oligodeoxynucleotides mimic autoantigens and reveal a potential role for Toll-like receptor 9 in receptor revision.

Authors:  Anne Doster; Saskia Ziegler; Sandra Foermer; Ralf Joachim Rieker; Klaus Heeg; Isabelle Bekeredjian-Ding
Journal:  Immunology       Date:  2013-06       Impact factor: 7.397

Review 3.  [Concepts on the pathogenesis of juvenile idiopathic arthritis].

Authors:  T Niehues; O Feyen; T Telieps
Journal:  Z Rheumatol       Date:  2008-03       Impact factor: 1.372

4.  B-cell pathology in juvenile idiopathic arthritis.

Authors:  V Wiegering; H J Girschick; H Morbach
Journal:  Arthritis       Date:  2010-12-02

Review 5.  B Cells as a Therapeutic Target in Paediatric Rheumatic Disease.

Authors:  Meredyth G Ll Wilkinson; Elizabeth C Rosser
Journal:  Front Immunol       Date:  2019-02-14       Impact factor: 7.561

Review 6.  B Cells on the Stage of Inflammation in Juvenile Idiopathic Arthritis: Leading or Supporting Actors in Disease Pathogenesis?

Authors:  Rita A Moura; João Eurico Fonseca
Journal:  Front Med (Lausanne)       Date:  2022-04-04

7.  Abatacept in difficult-to-treat juvenile idiopathic arthritis.

Authors:  Jasmin B Kuemmerle-Deschner; Sm Benseler
Journal:  Biologics       Date:  2008-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.